Genetics change GLP‑1 response
New studies show that genetic differences can predict who benefits most from GLP‑1 weight-loss drugs and who is likelier to get side effects like nausea, while regulators also approved a new oral GLP‑1 this week. Nature and Scientific American report that variants in two genes are linked to weight-loss response and adverse effects, and the FDA’s approval of Foundayo gives patients an oral alternative to injectable options like Wegovy. ( )
Glucagon-like peptide 1 is a gut hormone your body releases after you eat, and drugs that mimic it make food move more slowly and appetite fade sooner. That is why medicines like semaglutide and tirzepatide can help people lose large amounts of weight, but the results vary a lot from person to person. (nature.com) That spread is wide enough that some people lose less than 5% of body weight while others lose more than 20% on the same class of drugs. A new Nature study looked at 27,885 people who reported their weight loss and side effects after taking glucagon-like peptide 1 receptor agonists to see whether DNA helps explain the gap. (nature.com) The first gene the researchers focused on was GLP1R, which is the instruction manual for the receptor these drugs are designed to hit. If the receptor is the lock, the drug is the key, so even a small change in that lock can change how strongly the medicine works. (nature.com) They found a missense variant in GLP1R linked to better weight-loss response, with about 0.76 kilograms of extra weight loss per copy of the effect allele. Scientific American reported that this kind of common genetic difference could help explain why nearly one in four people do not respond much to these medicines at all. (nature.com, scientificamerican.com) The second gene was GIPR, which helps the body respond to another gut hormone called gastric inhibitory polypeptide. That mattered most for tirzepatide, because tirzepatide targets both the glucagon-like peptide 1 pathway and the gastric inhibitory polypeptide pathway, while semaglutide mainly targets the first one. (nature.com) The side effect the study tracked was nausea or vomiting, which is one of the main reasons people stop these drugs early. The researchers found links between nausea risk and variation in both GLP1R and GIPR, with the GIPR signal showing up only in tirzepatide users. (nature.com) The point is not that a gene test can already tell you exactly how many pounds you will lose. The Nature paper says the variants were folded into a broader prediction model that could sort patients by likely benefit and side-effect risk, which is closer to a weather forecast than a guarantee. (nature.com) This landed in the same week the Food and Drug Administration approved Foundayo, the brand name for orforglipron, as a once-daily tablet for adults with obesity or adults with overweight plus at least one weight-related condition. The agency said the pill should be used with a reduced-calorie diet and more physical activity, and it does not need to be taken on an empty stomach. (fda.gov) Foundayo is not just another brand swap, because it gives patients a pill instead of a weekly shot. The Food and Drug Administration said it approved the drug on April 1, 2026, just 50 days after filing, and called it the fastest approval of a new molecular entity since 2002. (fda.gov) Scientific American reported that Foundayo produced an average of 27 pounds of weight loss over 72 weeks, adding a second approved pill to a market that had been dominated by injections. Put together, the week’s two stories point to a more customized version of obesity treatment: one shift in how the drug is taken, and another in how doctors may eventually decide which drug to try first. (scientificamerican.com, fda.gov)
